Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 192,682 shares, a decline of 67.1% from the April 30th total of 586,422 shares. Approximately 1.9% of the shares of the company are sold short. Based on an average daily trading volume, of 138,014 shares, the short-interest ratio is presently 1.4 days.

Cocrystal Pharma Trading Down 0.9%

Shares of NASDAQ:COCP traded down $0.01 during trading on Friday, reaching $1.12. The company’s stock had a trading volume of 101,603 shares, compared to its average volume of 130,481. Cocrystal Pharma has a 12 month low of $0.86 and a 12 month high of $2.67. The firm’s 50 day simple moving average is $1.29 and its two-hundred day simple moving average is $1.11. The stock has a market capitalization of $15.44 million, a PE ratio of -1.53 and a beta of 1.50.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. Research analysts anticipate that Cocrystal Pharma will post -0.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Institutional Trading of Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent reporting period. 6.72% of the stock is owned by hedge funds and other institutional investors.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.